抗SRP抗体陽性の重症多発性筋炎に免疫グロブリン大量療法(IVIG)が奏効した一例

    The idiopathic inflammatory myopathies are systemic autoimmune diseases characterized by chronic inflammation, leading to progressive weakness of the proximal muscles. Myositis-specific or associated autoantibodies are often found in the serum of polymyositis (PM) and dermatomyositis patients. A...

Full description

Saved in:
Bibliographic Details
Published in臨床リウマチ Vol. 26; no. 1; pp. 63 - 68
Main Authors 田崎, 知江美, 木下, 浩二, 嶋津, 秀紀, 井上, 明日圭, 廣岡, 靖章, 朝戸, 佳世, 岸本, 和也, 樋野, 尚一, 志賀, 俊彦, 松村, 到, 船内, 正憲, 矢野, 智洋, 野﨑, 祐史, 李, 進海, 湯本, 妙子
Format Journal Article
LanguageJapanese
Published 一般社団法人 日本臨床リウマチ学会 2014
The Japanese Society for Clinical Rheumatology and Related Research
Subjects
Online AccessGet full text
ISSN0914-8760
2189-0595
DOI10.14961/cra.26.63

Cover

More Information
Summary:    The idiopathic inflammatory myopathies are systemic autoimmune diseases characterized by chronic inflammation, leading to progressive weakness of the proximal muscles. Myositis-specific or associated autoantibodies are often found in the serum of polymyositis (PM) and dermatomyositis patients. Anti-SRP (signal recognition particle) antibody is thought to be associated with severe forms of the disease, particularly those with heart and lung involvement and resistant to adrenocorticosteroids. We present a66-year-old female polymyositis patient with serious muscle weakness and high CPK level (21550IU/L). Despite initial therapy with high-dose methylprednisolone (1g/day x3days,i.v.) followed by prednisolone (1mg/kg/day,p.o.) plus cyclosporine A (150mg/day), muscle weakness was not improved and CPK levels were not reduced to less than3000IU/L. After treatment with intravenous immunoglobulin (IVIG), muscle strength was gradually improved and CPK levels were reduced to less than700IU/L. To our knowledge, there were few reports that PM positive for serum anti-SRP antibody treated with IVIG. IVIG might be a therapeutic agent of choice for steroid-resistant cases of serum anti-SRP antibody-positive PM.
ISSN:0914-8760
2189-0595
DOI:10.14961/cra.26.63